Intelligencia AI Awarded U.S. Patent for Its Accurate and Transparent Probability of Drug Success Assessments
AIT365 News Desk -
Intelligencia AI, a provider of AI-powered solutions that support data-driven decision-making in drug development, announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,948,667 on April 2, 2024.
The patent titled,"System and Interfaces for Processing and Interacting With Clinical Data,” pertains to the company's novel techniques for training...
Agilent Technologies Inc. announced the launch of the Advanced Dilution System, the ADS 2, a new automation workflow solution that will increase productivity, lower cost of ownership, and improve the overall efficiency within the laboratory.
The Agilent ADS 2 is an intelligent autodilutor designed to enhance laboratory workflows. Designed to...
Turbine and Harmonic Discovery Pair Simulation-Guided Biology and Multi-Target Kinase Inhibition Chemistry Expertise to Develop a Novel Cancer Therapy
AIT365 News Desk -
Companies will co-develop inhibitors of a dark kinase target (NEK1) identified for cancer dependency by Turbine’s Simulated Cell™ platform
Turbine, a company that is building the world’s first predictive simulation of patient biology, and Harmonic Discovery (Harmonic), a therapeutics company building an integrated computational and experimental platform for kinase drug discovery...
Maplight Therapeutics Announces Initiation Of Phase 1 Clinical Trial For Ml-007/Pac, Under Development For Schizophrenia And Alzheimer’s Disease Psychosis
AIT365 News Desk -
MapLight Therapeutics, a clinical-stage biopharmaceutical company working to develop targeted novel therapeutics to improve the lives of patients suffering from debilitating CNS disorders, announced initiation of a Phase 1 clinical trial evaluating ML-007/PAC, MapLight's extended-release fixed-dose combination formulation of the novel, investigational muscarinic agonist ML-007 and a precision-matched peripherally...
SyntheticMR receives FDA 510(k) clearance for their next Generation Solution SyMRI 3D
AIT365 News Desk -
SyntheticMR announced that their next-generation imaging solution with isotropic resolution, SyMRI 3D, has received FDA 510(k) clearance for clinical use in the United States.
SyntheticMR is proud to announce that its next-generation imaging solution, SyMRI 3D, has received FDA 510(k) clearance for clinical use in the United States. This milestone...
Cleerly® ISCHEMIA™ Demonstrates Robust Diagnostic Accuracy and Prognostic Utility in Analyses from Large Scale Clinical Trials
AIT365 News Desk -
Cleerly, the company on a mission to create a new standard of care to aid in the diagnosis of heart disease, shared findings from a study published online in the Journal of the American College of Cardiology: Cardiovascular Imaging. The study describes the validation of Cleerly's artificial intelligence-guided quantitative...
XtalPi Inc., a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials, announced the launch of its proprietary comprehensive solid form discovery and selection platform, XtalGazer. This advanced platform aims to significantly improve the polymorph selection process...
Noetik, an AI-native biotechnology company leveraging advanced machine learning and proprietary data to discover and develop precision cancer immunotherapies announces the appointment of Dr. Shafique Virani as Chief Business Officer. Dr. Virani brings a rich background in both business development and clinical development, with experience building therapeutics portfolios at...
Iambic Therapeutics Announces First Patient Dosed in Phase 1 Clinical Study of IAM1363, a Highly Selective HER2 Inhibitor for the Treatment of Solid Tumors
AIT365 News Desk -
Iambic Therapeutics, a biotechnology company developing novel therapeutics using its unique AI-driven discovery platform, announced that the first patient has been dosed in its Phase 1 clinical study evaluating IAM1363, a selective and brain-penetrant inhibitor of HER2 signaling for the treatment of HER2-driven cancers.
“Using Iambic’s AI platform, we have...
Lunit SCOPE IO Reveals Promising Results in Neoadjuvant Immunotherapy Study for Head and Neck Cancer Patients
AIT365 News Desk -
Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced the publication of a new study featuring Lunit SCOPE IO, Lunit's AI-powered analyzer for quantitative immune phenotyping from H&E. The study was recently published in Clinical Cancer Research (CCR), an international journal by the American Association for...